SC&H Financial Advisors Inc. Lowers Holdings in Zoetis Inc. (NYSE:ZTS)

SC&H Financial Advisors Inc. decreased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 13.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,304 shares of the company’s stock after selling 363 shares during the quarter. SC&H Financial Advisors Inc.’s holdings in Zoetis were worth $455,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in ZTS. International Assets Investment Management LLC raised its stake in shares of Zoetis by 25.1% in the third quarter. International Assets Investment Management LLC now owns 1,726 shares of the company’s stock worth $302,000 after purchasing an additional 346 shares during the last quarter. Legacy Capital Wealth Partners LLC purchased a new position in shares of Zoetis in the third quarter worth $221,000. Rothschild Investment LLC IL purchased a new position in shares of Zoetis in the third quarter worth $380,000. First Affirmative Financial Network purchased a new position in shares of Zoetis in the third quarter worth $238,000. Finally, McBroom & Associates LLC raised its stake in shares of Zoetis by 14.6% in the third quarter. McBroom & Associates LLC now owns 31,354 shares of the company’s stock worth $5,455,000 after purchasing an additional 4,000 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on the company. Stifel Nicolaus cut their price objective on Zoetis from $215.00 to $195.00 and set a “buy” rating for the company in a report on Tuesday, April 2nd. StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Barclays lifted their price objective on Zoetis from $255.00 to $260.00 and gave the stock an “overweight” rating in a report on Wednesday, February 14th. Piper Sandler reaffirmed an “overweight” rating and issued a $195.00 price objective (down previously from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Finally, The Goldman Sachs Group lifted their price objective on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $221.75.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 363 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $197.74, for a total transaction of $71,779.62. Following the transaction, the executive vice president now owns 20,417 shares of the company’s stock, valued at $4,037,257.58. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold a total of 2,209 shares of company stock worth $371,293 over the last ninety days. Company insiders own 0.15% of the company’s stock.

Zoetis Stock Performance

NYSE:ZTS traded down $0.96 during mid-day trading on Monday, hitting $145.54. 4,545,035 shares of the company traded hands, compared to its average volume of 3,048,813. The firm has a market cap of $66.56 billion, a price-to-earnings ratio of 28.79, a price-to-earnings-growth ratio of 2.24 and a beta of 0.85. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. The stock’s fifty day moving average price is $175.48 and its 200-day moving average price is $180.15. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). The business had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The business’s revenue was up 8.5% on a year-over-year basis. During the same period last year, the company earned $1.15 EPS. Research analysts anticipate that Zoetis Inc. will post 5.79 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be given a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a yield of 1.19%. Zoetis’s dividend payout ratio (DPR) is presently 34.12%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.